Study 29 – Genetics Protocol of the Cocaine Use Reduction with Buprenorphine (CURB) Study; CTN-0048

Investigators:  David A. Nielsen, Ph.D., Thomas R. Kosten, M.D. (Baylor College of Medicine), Walter Ling, M.D. (UCLA)

Status: Available at NIDA Repository

Release Date:  August 2023

Abstract:  This was a randomized, controlled trial that enrolled 302 cocaine-dependent participants who had either past-year opioid dependence or past-year opioid abuse or past-year opioid use with a history of opioid dependence during the lifetime. Participants were randomized to one of three treatment arms: 1) placebo plus naltrexone, 2) 4mg buprenorphine plus naltrexone, and 3) 16mg buprenorphine plus naltrexone. Participants received 8 weeks of pharmacotherapy, with thrice weekly clinic visits. The primary aim of the study was to compare the number of cocaine use days during the 30-day evaluation period (the final 30 days of active medication administration prior to taper; days 25-54) amongst the treatment groups. The study also evaluated a number of secondary outcome measures.


No instrument available